As previously reported, Credit Suisse analyst Martin Auster upgraded United Therapeutics to Neutral from Underperform, with a $98 price target. The analyst believes the stock has baked-in most of the recent negative developments, namely lackluster FREEDOM-EV results, BEAT trial failure, the launch of generic Remodulin, and a declining forward-looking EPS profile. At current levels, Auster is more inclined to be constructive on the name on further weakness as he thinks a fairly aggressive generic Remodulin scenario is being baked-in, but remains on the sidelines on limited visibility for now on a more attenuated erosion.